1
|
Çiçek İ, Tunç T, Ogutcu H, Abdurrahmanoglu S, Günel A, Demirel N. Synthesis and Antibacterial Activity of New Chiral Aminoalcohol and Benzimidazole Hybrids. ChemistrySelect 2020. [DOI: 10.1002/slct.202000355] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- İlknur Çiçek
- Department of Chemistry, Faculty of Arts and SciencesAhi Evran University 40100 Kırşehir Turkey
| | - Turgay Tunç
- Department of Chemistry Engineering and Process, Faculty of EngineeringUniversity of Ahi Evran Kırsehir 40100 Turkey
| | - Hatice Ogutcu
- Department of Field Crops, Faculty of AgricultureUniversity Ahi Evran Kırsehir 40100 Turkey
| | - Suzan Abdurrahmanoglu
- Department of ChemistryFaculty of Arts and Science, Marmara University Istanbul 34722 Turkey
| | - Aslıhan Günel
- Department of Chemistry, Faculty of Arts and SciencesAhi Evran University 40100 Kırşehir Turkey
| | - Nadir Demirel
- Department of Chemistry, Faculty of Arts and SciencesAhi Evran University 40100 Kırşehir Turkey
| |
Collapse
|
2
|
Shin D, Park SI, Lee HS, An KM, Jung J, Lee M, Yu KS. Pharmacokinetics and tolerability of IDP-73152 mesylate after a single oral administration under fasted and fed conditions in healthy volunteers. DRUG DESIGN DEVELOPMENT AND THERAPY 2019; 13:2483-2490. [PMID: 31440032 PMCID: PMC6664420 DOI: 10.2147/dddt.s209238] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Accepted: 07/03/2019] [Indexed: 12/30/2022]
Abstract
Background and objective IDP-73152 mesylate is a peptide deformylase inhibitor under investigation for the treatment of complicated skin and respiratory tract infections. The objective of this study was to investigate the pharmacokinetic (PK) profile and tolerability of IDP-73152 and the effect of food after a single oral administration. Methods A dose block-randomized, double-blind, placebo-controlled, dose-escalation study was conducted. A total of 56 healthy volunteers received IDP-73152 mesylate in a single oral dose of 40, 80, 160, 320, 640, or 1280 mg in the fasted and fed (640 mg only) states. Blood and urine samples for PK analysis were collected up to 48 h post dose. Results The area under the plasma concentration-time curve (AUC0-t) of IDP-73152 increased in a dose-proportional manner in the range of 40-320 mg. The mean terminal half-life decreased from 10.7 to 6.2 hrs as the dose increased. The fraction excreted unchanged in the urine ranged from 0.05 to 0.12. In the 640-mg dose group, food delayed the median time to peak concentration (t max) from 0.9 to 3.5 hrs. Furthermore, the maximum plasma concentration (Cmax) were decreased by 36.2%; however, AUC0-t was not generally affected. No serious adverse event or clinically significant findings were observed. Conclusions The systemic exposure of IDP-73152 proportionally increased as the dose increased up to 320 mg. The rate of absorption and extent of exposure were reduced by food intake. IDP-73152 was well tolerated without clinically significant adverse effects after a single oral administration.
Collapse
Affiliation(s)
- Dongseong Shin
- Department of Pharmacology, Gachon University College of Medicine, Incheon, Korea.,Clinical Trials Center, Gachon University Gil Medical Center, Incheon, Korea.,Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea
| | - Sang-In Park
- Department of Clinical Pharmacology and Therapeutics, Kyung Hee University Hospital, Seoul, Korea.,East-West Medical Research Institute, Kyung Hee University, Seoul, Korea
| | - Hong-Sub Lee
- Research Laboratories ILDONG Pharmaceutical Co. Ltd, Hwaseong, Korea
| | - Kyung-Mi An
- Research Laboratories ILDONG Pharmaceutical Co. Ltd, Hwaseong, Korea
| | - Juyoung Jung
- Research Laboratories ILDONG Pharmaceutical Co. Ltd, Hwaseong, Korea
| | - MyongJae Lee
- Research Laboratories ILDONG Pharmaceutical Co. Ltd, Hwaseong, Korea
| | - Kyung-Sang Yu
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea
| |
Collapse
|
3
|
Structure of the Ni(II) complex of Escherichia coli peptide deformylase and suggestions on deformylase activities depending on different metal(II) centres. J Biol Inorg Chem 2009; 15:195-201. [DOI: 10.1007/s00775-009-0583-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
4
|
Sharma A, Sharma S, Khuller G, Kanwar A. In vitro and ex vivo activity of peptide deformylase inhibitors against Mycobacterium tuberculosis H37Rv. Int J Antimicrob Agents 2009; 34:226-30. [DOI: 10.1016/j.ijantimicag.2009.04.005] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2008] [Revised: 02/27/2009] [Accepted: 04/05/2009] [Indexed: 11/17/2022]
|
5
|
Sharma A, Khuller GK, Sharma S. Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery. Expert Opin Ther Targets 2009; 13:753-65. [PMID: 19530983 DOI: 10.1517/14728220903005590] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
BACKGROUND Tuberculosis (TB) remains the most important infectious disease causing morbidity and death, due to the human pathogen Mycobacterium tuberculosis. The emergence of multi-drug-resistant and extensively-drug-resistant forms of TB have resulted in an increase in the number of TB cases. Thus, there is an urgent need to identify new drugs with novel targets to ensure future therapeutic success. Studies have indicated that peptide deformylase is an interesting potential candidate for discovering antimicrobial agents. OBJECTIVE To explore the role of peptide deformylase, a highly conserved metalloprotease and an essential enzyme in bacterial life cycle, as a target for antibacterial as well as antimycobacterial drug development. METHODS This review is based on recent published literature and online resources related to peptide deformylase inhibitors and their antibacterial potential. RESULTS/CONCLUSION Peptide deformylase is an emerging therapeutic target for the treatment of tuberculosis and peptide deformylase inhibitors can act as potential future antibacterial agents.
Collapse
Affiliation(s)
- Anshika Sharma
- University of Notre Dame, Department of Biological Sciences, Notre Dame, IN-46556, USA
| | | | | |
Collapse
|
6
|
Wang Q, Wang J, Cai Z, Xu W. Prediction of the binding modes between BB-83698 and peptide deformylase from Bacillus stearothermophilus by docking and molecular dynamics simulation. Biophys Chem 2008; 134:178-84. [DOI: 10.1016/j.bpc.2008.02.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2007] [Revised: 02/10/2008] [Accepted: 02/11/2008] [Indexed: 11/30/2022]
|
7
|
Huang J, Van Aller GS, Taylor AN, Kerrigan JJ, Liu WS, Trulli JM, Lai Z, Holmes D, Aubart KM, Brown JR, Zalacain M. Phylogenomic and biochemical characterization of three Legionella pneumophila polypeptide deformylases. J Bacteriol 2006; 188:5249-57. [PMID: 16816197 PMCID: PMC1539947 DOI: 10.1128/jb.00866-05] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Legionella pneumophila is a gram-negative facultative intracellular human pathogen that can cause fatal Legionnaires' disease. Polypeptide deformylase (PDF) is a novel broad-spectrum antibacterial target, and reports of inhibitors of PDF with potent activities against L. pneumophila have been published previously. Here, we report the identification of not one but three putative pdf genes, pdfA, pdfB, and pdfC, in the complete genome sequences of three strains of L. pneumophila. Phylogenetic analysis showed that L. pneumophila PdfA is most closely related to the commonly known gamma-proteobacterial PDFs encoded by the gene def. PdfB and PdfC are more divergent and do not cluster with any specific bacterial or eukaryotic PDF. All three putative pdf genes from L. pneumophila strain Philadelphia 1 have been cloned, and their encoded products have been overexpressed in Escherichia coli and purified. Enzymatic characterization shows that the purified PDFs with Ni2+ substituted are catalytically active and able to remove the N-formyl group from several synthetic polypeptides, although they appear to have different substrate specificities. Surprisingly, while PdfA and PdfB with Zn2+ substituted are much less active than the Ni2+ forms of each enzyme, PdfC with Zn2+ substituted was as active as the Ni2+ form for the fMA substrate and exhibited substrate specificity different from that of Ni2+ PdfC. Furthermore, the catalytic activities of these enzymes are potently inhibited by a known small-molecule PDF inhibitor, BB-3497, which also inhibits the extracellular growth of L. pneumophila. These results indicate that even though L. pneumophila has three PDFs, they can be effectively inhibited by PDF inhibitors which can, therefore, have potent anti-L. pneumophila activity.
Collapse
Affiliation(s)
- Jianzhong Huang
- Microbiology Department, GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, PA 19426, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Abstract
Peptide deformylase (PDF) is an attractive target for antibacterial drug discovery. Progress in the biological characterisation of the enzyme, coupled with newly obtained mechanistic and structural insight, enabled the pharmaceutical industry to discover potent PDF inhibitors that can be considered as clinical development candidates for this new class of antibacterial agents. The in vitro and in vivo data for several lead PDF inhibitors suggest that the current PDF inhibitors are most suitable for the treatment of respiratory tract infections and they are not cross-resistant to the current clinically used antibiotics. Two PDF inhibitors, BB-83698 and VIC-104959, have progressed to Phase I clinical trials by intravenous and oral administration, respectively. Both of these compounds show promising in vitro and in vivo efficacy and an excellent safety profile. The pharmacokinetics in humans for both of the compounds suggest the possibility of a twice-daily dosing regimen for clinical use. Thus far, all of the data suggest a promising future for this new class of antibacterial agents.
Collapse
Affiliation(s)
- D Chen
- Vicuron Pharmaceuticals, 34790 Ardentech Court, Fremont, CA 94555, USA
| | | |
Collapse
|
9
|
Yuan Z, White RJ. The evolution of peptide deformylase as a target: contribution of biochemistry, genetics and genomics. Biochem Pharmacol 2005; 71:1042-7. [PMID: 16289392 DOI: 10.1016/j.bcp.2005.10.015] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2005] [Revised: 10/05/2005] [Accepted: 10/06/2005] [Indexed: 11/15/2022]
Abstract
Although peptide deformylase (PDF, EC 3.5.1.27) was first described in 1968, the instability of enzyme preparations prevented it from being seriously considered as a target until this problem was finally solved in 1998. PDFs essentiality was first demonstrated in Escherichia coli in 1994. Genomic analyses have shown this enzyme to be present in all eubacteria. PDF homologs have also been found in eukaryotes including Homo sapiens. The function and relevance of the human chromosomal homolog to the safety of PDF inhibitors as therapeutic agents is not clear at this stage. Although there is considerable sequence variation between the different bacterial PDFs, there are three strongly conserved motifs that together constitute a critical metal binding site. The observation that PDF is a metalloenzyme has led to the design of inhibitors containing metal chelating pharmacophores. The most potent of these synthetic inhibitors are active against a range of clinically relevant respiratory tract pathogens in vitro and in vivo, including those resistant to current antibiotics. Mutants resistant to PDF inhibitors have been obtained in the laboratory; these resulted from mutations in the genes for transformylase (EC 2.1.2.9) or PDF. The mechanism involved and its frequency were pathogen-dependent. The two most advanced PDF inhibitor leads, which are both reverse hydroxamates, have progressed to phase 1 clinical trials and were well tolerated.
Collapse
Affiliation(s)
- Zhengyu Yuan
- Vicuron Pharmaceuticals Inc., 34790 Ardentech Court, Fremont, CA 94555, USA
| | | |
Collapse
|
10
|
Molteni V, Kreusch A. Peptide deformylase inhibitors: a survey of the patent literature. Expert Opin Ther Pat 2005. [DOI: 10.1517/13543776.15.10.1423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
11
|
Bell JM, Turnidge JD, Inoue M, Kohno S, Hirakata Y, Ono Y, Jones RN. Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan. J Antimicrob Chemother 2005; 55:276-8. [PMID: 15649992 DOI: 10.1093/jac/dkh547] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Ramanathan-Girish S, McColm J, Clements JM, Taupin P, Barrowcliffe S, Hevizi J, Safrin S, Moore C, Patou G, Moser H, Gadd A, Hoch U, Jiang V, Lofland D, Johnson KW. Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrob Agents Chemother 2005; 48:4835-42. [PMID: 15561864 PMCID: PMC529202 DOI: 10.1128/aac.48.12.4835-4842.2004] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
BB-83698, a potent and selective inhibitor of peptide deformylase, was the first compound of this novel antibacterial class to progress to clinical trials. Single- and/or multiple-dose studies with doses ranging from 10 to 50 mg of BB-83698/kg of body weight were done with mice, rats, and dogs. Intravenous pharmacokinetics were characterized by low to moderate clearances and moderate volumes of distribution for all species. In dogs, but not in rodents, central nervous system (CNS) effects were dose limiting for intravenously administered BB-83698 and were suspected to be related to a high maximum concentration of the agent in plasma (Cmax) rather than to total systemic exposure. Controlled infusion studies with dogs demonstrated that CNS effects could be avoided without compromising systemic exposure by reducing the Cmax. A randomized, double-blind, placebo-controlled, five-way-crossover, single-dose-escalation, phase I study to explore the safety, tolerability, and pharmacokinetics of intravenous BB-83698 at doses ranging from 10 to 475 mg was performed with healthy male volunteers. Systemic exposures were generally in linear relationships with administered doses in animals and humans. Pharmacokinetics were consistent, predictable, and exhibited good allometric scaling among all species (r2 >0.98). Moreover, BB-83698 dosing in humans proceeded to a predicted efficacious exposure (the area under the concentration-time curve/MIC ratio, up to 184) without any clinically significant adverse effects.
Collapse
|
13
|
Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, Pei D. Macrocyclic Inhibitors for Peptide Deformylase: A Structure−Activity Relationship Study of the Ring Size. J Med Chem 2004; 47:4941-9. [PMID: 15369398 DOI: 10.1021/jm049592c] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Peptide deformylase (PDF) catalyzes the removal of the N-terminal formyl group from newly synthesized polypeptides in eubacteria. Its essential role in bacterial cells but not in mammalian cells makes it an attractive target for antibacterial drug design. We have previously reported an N-formylhydroxylamine-based, metal-chelating macrocyclic PDF inhibitor, in which the P(1)' and P(3)' side chains are covalently joined. In this work, we have carried out a structure-activity relationship study on the size of the macrocycle and found that 15-17-membered macrocycles are optimal for binding to the PDF active site. Unlike the acyclic compounds, which are simple competitive inhibitors, the cyclic compounds all act as slow-binding inhibitors. As compared to their acyclic counterparts, the cyclic inhibitors displayed 20-50-fold higher potency against the PDF active site (K(I) as low as 70 pM), improved selectivity toward PDF, and improved the metabolic stability in rat plasma. Some of the macrocyclic inhibitors had potent, broad spectrum antibacterial activity against clinically significant Gram-positive and Gram-negative pathogens. These results suggest that the macrocyclic scaffold provides an excellent lead for the development of a new class of antibiotics.
Collapse
Affiliation(s)
- Xubo Hu
- Department of Chemistry and Ohio State Biochemistry Program, The Ohio State University, 100 West 18th Avenue, Columbus, Ohio 43210, USA
| | | | | | | | | | | |
Collapse
|